Loading…
Loading grant details…
| Funder | NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE |
|---|---|
| Recipient Organization | Washington University |
| Country | United States |
| Start Date | Jul 15, 2024 |
| End Date | Jun 30, 2026 |
| Duration | 715 days |
| Number of Grantees | 1 |
| Roles | Principal Investigator |
| Data Source | NIH (US) |
| Grant ID | 10952676 |
Modeling human adult-onset neurodegenerative diseases has been historically difficult, with current induced pluripotent stem cell (iPSC) models often showing mild phenotypes. While iPSC systems capture disease-associated genetic variants, generating these cells erases cellular age – a critical component of many
neurodegenerative diseases. An alternative approach is the direct conversion of fibroblasts into neurons, which preserves the epigenetic age of the starting cells. As such, this approach has been highly successful in modeling pathologies of various neurodegenerative diseases including tauopathies, Huntington’s disease, and Alzheimer’s
disease. In the proposed research project, we will employ direct neuronal conversion as a new tool to investigate amyotrophic lateral sclerosis (ALS) and associated frontotemporal dementia (FTD). We will initially study familial ALS cells that have been converted into induced motor neurons and subsequently probe for neurodegenerative
phenotypes. We have already observed stress-induced degeneration in the context of multiple ALS-associated mutations. Removal of epigenetic age via iPSC conversion and antisense oligonucleotide knockdown of mutant proteins will establish the specificity of this system. We will further expand our studies to sporadic ALS lines,
investigating neurodegeneration-associated features including nuclear pore deficits. Finally, cells from ALS/FTD patients will be converted into a cortical identity to provide a novel model for FTD. With these models, we can interrogate disease mechanisms in ALS/FTD. Further, the development of a tractable, patient-derived in vitro
model of familial and sporadic ALS would represent a considerable breakthrough for the ALS research community, facilitating the eventual development of novel therapeutic agents.
Washington University
Complete our application form to express your interest and we'll guide you through the process.
Apply for This Grant